CF AMR Syndicate

ABOUT US

Medicines Discovery Catapult has joined forces with the Cystic Fibrosis Trust to form the Cystic Fibrosis (CF) Syndicate in Antimicrobial Resistance (AMR).
The CF AMR Syndicate brings industry leaders and people with CF together with academics with expertise in CF and pulmonary infection.

The unmet need
Cystic Fibrosis (CF)is a life-limiting disease affecting over 10,600 people in the UK.
People with CF experience a build-up of thick sticky mucus in their lungs and other organs, which leads to the development of frequent and persistent infections that are difficult to treat.

AMR is frequently seen in people with CF, who die from antibiotic failures.
The discovery and development of new antimicrobials to treat infections associated with CF are undoubted, an urgent unmet need.

The CF Syndicate in AMR
The CF Syndicate in AMR has been set up to accelerate the translation of CF antimicrobials to the clinic to bring new and effective treatment options to people with CF.

Our research agenda has been informed by extensive efforts to understand the research landscape and the needs for CF infections. Research within the community has been developed through a cross-sector collaborative approach, which has involved close working with people with CF.

To accelerate CF antimicrobial drug discovery and development, we are:

1. Creating resources for CF antimicrobial discovery and development
a) The CF AMR Biorepository enables access to high-quality samples and data, including
CF-relevant strains and isolates
b) The patient-focussed Target Product Profiles (TPPs) for CF-related infections provide
guidance in CF antimicrobial discovery and development to innovators in industry and
academia.

2. Building a CF AMR network to facilitate collaboration and enable knowledge exchange

3. Nurturing and supporting promising CF antimicrobial projects through dedicated support at
Medicines Discovery Catapult and the Trust

Our history
Since launching in September 2019, CF AMR Syndicate has:

● Involved people with CF in all our activities to ensure their needs and priorities are at the
heart of all Syndicate research efforts.
● Developed a strong understanding of the critical challenges and opportunities in CF
antimicrobial drug discovery.
● Established strong links and engaged widely with the international CF infection research
community in academia and industry.
● Created resources to support accelerating CF antimicrobial discovery and development efforts.

Contact CF AMR Syndicate
If you would like more information about what we do and our mission, please get in touch via the contact details below.

Email: [email protected]